Express News | Zyversa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome Asc Inhibitor Ic 100
Express News | ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.59%
ZyVersa Therapeutics Announces Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to Be Held Virtually on July 15, 2024
Peering Into ZyVersa Therapeutics's Recent Short Interest
Express News | Zyversa Therapeutics: Inflammasome Asc Inhibitor Ic 100's Preclinical Program Nearing Completion, Glp Toxicology Studies Expected to Begin H1-2024
Express News | ZyVersa Therapeutics Q1 2024 Adj EPS $(4.53) Misses $(3.70) Estimate
Express News | Zyversa Therapeutics Qtrly Shr Loss $4.53
ZyVersa Therapeutics 1Q Loss/Shr $4.53 >ZVSA
Express News | Zyversa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
10-Q: Quarterly report
10-K/A: Annual report (Amendment)
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
CRVS, CTMX and NRXP Are Among Premarket Gainers
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
What's Going On With ZyVersa Stock?
ZyVersa Therapeutics Stock Jumps 8%
Express News | ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt
ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings Among Healthcare Movers
PHG, IBRX and MESO Are Among Premarket Gainers
No Data